JP2020505342A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505342A5 JP2020505342A5 JP2019537357A JP2019537357A JP2020505342A5 JP 2020505342 A5 JP2020505342 A5 JP 2020505342A5 JP 2019537357 A JP2019537357 A JP 2019537357A JP 2019537357 A JP2019537357 A JP 2019537357A JP 2020505342 A5 JP2020505342 A5 JP 2020505342A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- antibody
- cells
- nrn1
- sema7a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 25
- 239000003814 drug Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 6
- 239000002955 immunomodulating agent Substances 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 238000002659 cell therapy Methods 0.000 claims 4
- 102000017578 LAG3 Human genes 0.000 claims 3
- 101150030213 Lag3 gene Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 claims 2
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims 2
- 101000738506 Homo sapiens Psychosine receptor Proteins 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 claims 2
- 101000640713 Homo sapiens Transmembrane protein 126A Proteins 0.000 claims 2
- 101000763430 Homo sapiens Transmembrane protein 205 Proteins 0.000 claims 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 claims 2
- 101150103083 NRN1 gene Proteins 0.000 claims 2
- 101150051337 NRP1 gene Proteins 0.000 claims 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 2
- 102100037860 Psychosine receptor Human genes 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims 2
- 102100033846 Transmembrane protein 126A Human genes 0.000 claims 2
- 102100027022 Transmembrane protein 205 Human genes 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- -1 GM156 Proteins 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 230000004186 co-expression Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022139514A JP2022184862A (ja) | 2017-01-17 | 2022-09-01 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447199P | 2017-01-17 | 2017-01-17 | |
| US62/447,199 | 2017-01-17 | ||
| PCT/US2018/014008 WO2018186924A1 (en) | 2017-01-17 | 2018-01-17 | Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022139514A Division JP2022184862A (ja) | 2017-01-17 | 2022-09-01 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505342A JP2020505342A (ja) | 2020-02-20 |
| JP2020505342A5 true JP2020505342A5 (enExample) | 2021-03-04 |
Family
ID=63712313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537357A Pending JP2020505342A (ja) | 2017-01-17 | 2018-01-17 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
| JP2022139514A Pending JP2022184862A (ja) | 2017-01-17 | 2022-09-01 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022139514A Pending JP2022184862A (ja) | 2017-01-17 | 2022-09-01 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11566077B2 (enExample) |
| EP (1) | EP3570887A4 (enExample) |
| JP (2) | JP2020505342A (enExample) |
| CN (1) | CN110740748A (enExample) |
| CA (1) | CA3049445A1 (enExample) |
| WO (1) | WO2018186924A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL265800B2 (en) | 2016-10-11 | 2023-10-01 | Agenus Inc | Anti-LAG-3 antibodies and methods of using them |
| JP7297672B2 (ja) | 2017-04-13 | 2023-06-26 | アジェナス インコーポレイテッド | 抗ｃｄ１３７抗体およびその使用方法 |
| US20220023342A1 (en) * | 2018-11-30 | 2022-01-27 | Institut Gustave Roussy | Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer |
| WO2020146772A1 (en) * | 2019-01-11 | 2020-07-16 | The Johns Hopkins University | Neuritin regulation of t cell anergy and t regulatory cell function |
| CN109913414A (zh) * | 2019-03-21 | 2019-06-21 | 吉林省银丰生物工程技术有限公司 | 肝癌afp特异性人工抗原递呈细胞诱导试剂盒 |
| US20210130438A1 (en) * | 2019-10-28 | 2021-05-06 | The Broad Institute, Inc. | Pan-cancer t cell exhaustion genes |
| WO2021146386A1 (en) * | 2020-01-14 | 2021-07-22 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases |
| CN115666655A (zh) * | 2020-03-17 | 2023-01-31 | 俄亥俄州立创新基金会 | 用于治疗兴奋性毒性的设计者胞外囊泡 |
| CN111781358A (zh) * | 2020-07-13 | 2020-10-16 | 张瑜 | Xab2蛋白作为卵巢癌预后和/或预测铂类耐药标志物 |
| CN112481375B (zh) * | 2020-08-27 | 2024-02-20 | 江苏大学 | 一种胃癌标志物及其应用 |
| CN114350616A (zh) * | 2022-01-24 | 2022-04-15 | 深圳市先康达生命科学有限公司 | 一种免疫细胞及其制备方法和应用 |
| CN114814231B (zh) * | 2022-03-08 | 2024-08-27 | 上海交通大学医学院附属瑞金医院 | 维甲酸诱导基因i在癌症治疗中的应用 |
| CN114561389A (zh) * | 2022-03-15 | 2022-05-31 | 南通市肿瘤医院 | Vrk1表达抑制剂及其应用 |
| CN115631857B (zh) * | 2022-04-01 | 2023-06-23 | 洛兮医疗科技(杭州)有限公司 | 甲状腺癌cd8+t细胞免疫相关基因预后预测模型 |
| CN114720691B (zh) * | 2022-05-10 | 2022-12-09 | 深圳粒影生物科技有限公司 | 一种检测生物标志物的试剂盒及其制备方法和应用 |
| CN115449548A (zh) * | 2022-09-20 | 2022-12-09 | 南京鼓楼医院 | Stac2卵丘细胞在评估卵母细胞受精能力中的应用 |
| CN117192127B (zh) * | 2023-08-18 | 2024-06-14 | 肇庆医学高等专科学校 | 一种hcc治疗靶点的发现方法 |
| CN119120385B (zh) * | 2024-11-14 | 2025-03-14 | 四川大学华西医院 | 一种具有长效抑瘤效果的嵌合抗原受体t细胞及其制备方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA877772B (en) | 1986-10-23 | 1988-04-20 | Amoco Corporation | Target and background capture methods and apparatus for affinity assays |
| US20070072209A1 (en) | 2005-07-07 | 2007-03-29 | Ashlee Moses | Methods of treatment and diagnosis of Kaposi's sarcoma (KS) and KS related diseases |
| WO2008133641A2 (en) * | 2006-10-11 | 2008-11-06 | Curagen Corporation | Antibodies directed to gpnmb and uses thereof |
| US8637084B2 (en) * | 2009-07-14 | 2014-01-28 | Asahi Kasei Medical Co., Ltd. | Treatment method for epithelial cancerous organism |
| WO2011159877A2 (en) * | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| JP2012025694A (ja) * | 2010-07-23 | 2012-02-09 | Asahi Kasei Kuraray Medical Co Ltd | 癌治療剤 |
| NZ714128A (en) * | 2010-09-09 | 2017-10-27 | Pfizer | 4-1bb binding molecules |
| SG190793A1 (en) | 2010-11-11 | 2013-07-31 | Agency Science Tech & Res | Targeting metabolic enzymes in human cancer |
| EP2911669B1 (en) * | 2012-10-26 | 2024-04-10 | The University of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| EP2970909A4 (en) * | 2013-03-15 | 2017-02-15 | The University of Chicago | Methods and compositions related to t-cell activity |
| EP3686219A1 (en) | 2014-02-04 | 2020-07-29 | Pfizer Inc | Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer |
| CN114107424A (zh) * | 2014-10-08 | 2022-03-01 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| JP6647315B2 (ja) * | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
| US20180371093A1 (en) * | 2015-12-17 | 2018-12-27 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| JP2019518791A (ja) | 2016-06-03 | 2019-07-04 | ザ・ブリガム・アンド・ウィメンズ・ホスピタルＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ | Ｋｌｒｇ１シグナリングセラピー |
-
2018
- 2018-01-17 US US16/476,219 patent/US11566077B2/en active Active
- 2018-01-17 CA CA3049445A patent/CA3049445A1/en active Pending
- 2018-01-17 EP EP18780614.6A patent/EP3570887A4/en active Pending
- 2018-01-17 JP JP2019537357A patent/JP2020505342A/ja active Pending
- 2018-01-17 CN CN201880016246.4A patent/CN110740748A/zh active Pending
- 2018-01-17 WO PCT/US2018/014008 patent/WO2018186924A1/en not_active Ceased
-
2022
- 2022-09-01 JP JP2022139514A patent/JP2022184862A/ja active Pending
-
2023
- 2023-01-06 US US18/151,112 patent/US20230416389A1/en not_active Abandoned
-
2024
- 2024-09-13 US US18/885,340 patent/US20250011452A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505342A5 (enExample) | ||
| Sharma et al. | Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy | |
| CN113286811B (zh) | 改善过继性细胞疗法的效力和安全性 | |
| Chester et al. | 4-1BB agonism: adding the accelerator to cancer immunotherapy | |
| Prieto et al. | Immunological landscape and immunotherapy of hepatocellular carcinoma | |
| JP2025013518A (ja) | Ｃａｒの抗腫瘍活性のための毒性管理 | |
| Fong et al. | Anti–cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment | |
| Aris et al. | Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment | |
| Park et al. | Immune therapeutics in the treatment of advanced gastric and esophageal cancer | |
| Wang et al. | Checkpoint blockade in combination with doxorubicin augments tumor cell apoptosis in osteosarcoma | |
| Wang et al. | What happens to the immune microenvironment after PD-1 inhibitor therapy? | |
| JP2017507936A5 (enExample) | ||
| JP7447011B2 (ja) | エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用 | |
| JP2015508816A5 (enExample) | ||
| Hebb et al. | Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression | |
| Niedbała et al. | Glioblastoma: pitfalls and opportunities of immunotherapeutic combinations | |
| JP2022523804A (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| Li et al. | Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments | |
| Pourhamzeh et al. | Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma | |
| Ohmine et al. | Novel immunotherapies in multiple myeloma | |
| US20230096897A1 (en) | Lymphocyte Population and Methods for Producing Same | |
| Mandalà et al. | Rational combination of cancer immunotherapy in melanoma | |
| Shah et al. | Multiple myeloma, targeting B-cell maturation antigen with chimeric antigen receptor T-cells | |
| Zhang et al. | Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors |